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The Global Virus Network (GVN) was established in 2011 in order to strengthen research and responses
to current viral causes of human disease and to prepare against new viral pandemic threats. There are
now 38 GVN Centers of Excellence and 6 Affiliate laboratories in 24 countries. GVN scientists meet
annually to learn about each other's current research, address collaborative priorities and plan future
programs. The 2016 meeting was held from October 23e25 in Hokkaido, Japan, in partnership with the
Japanese Society for Virology, the National Institute of Infectious Diseases of Japan and the Research
Center for Zoonosis Control of Hokkaido University. This report highlights the accomplishments of GVN
researchers in many priority areas of medical virology, including the current Zika epidemic, infections by
human papillomavirus, influenza, Ebola, Lassa, dengue, HIV, hepatitis C, and chikungunya viruses, and
the development of improved diagnostics and new vaccines.
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The Global Virus Network (GVN) was established in 2011 in
order to strengthen research in response to viral causes of human
disease and to prepare for new viral pandemic threats (Mann,
2011). The GVN now has 38 Centers of Excellence and 6 Affiliates
in 24 countries. Network scientists meet annually to address
research and collaborative priorities, learn about each member's
current work and plan future programs. These international con-
ferences have become critical platforms for the exchange of ideas
(for further information, go to http://www.gvn.org).
The 2016 international GVN meeting was held from October
23e25 in Hokkaido, Japan, in partnership with the Japanese Society
for Virology (JSV), the National Institute of Infectious Diseases of
Japan and the Research Center for Zoonosis Control of Hokkaido
University. It brought together directors of GVN Centers and their
colleagues for two days of scientific presentations and discussions
of emerging and re-emerging viral threats. This meeting report
highlights accomplishments of GVN researchers in many priority
areas of human virology, including the current Zika epidemic, in-
fections by human papillomavirus, influenza, Ebola, Lassa, dengue,
HIV, hepatitis C and chikungunya viruses, and the development of
improved diagnostics and new vaccines.
The Sapporo meeting was the first GVN event held jointly with a
local national virology society. More than 1000 JSV members had
the opportunity to attend scientific sessions, thereby expanding
opportunities for collaborative dialogue, particularly with young
Japanese virologists. The main objectives of the meeting were to
present and discuss current findings in medical virology, including
advances in research on HIV vaccines and other important retro-
viruses; provide a framework to encourage collaborations among
world experts; and address the GVN's annual strategy for continued
development.2. The Global Virus Network
The GVN was founded because there was no research organi-
zation independent of national governments which had the depth
of expertise needed to respond promptly to new pandemic viral
outbreaks and to prepare for such outbreaks. The GVN was not
intended to replace organizations such as the Centers for Disease
Control and Prevention (CDC) or the World Health Organization
(WHO), but to complement their activities with independent
opinions and expertise. In parallel, a second major goal of the GVN
was to advocate for the strengthening of virology as a core disci-
pline in infectious diseases and to help develop the next generation
of virologists (DiMaio, 2014).
In March 2011, 30 of the world's leading virologists gathered in
Washington, D.C. to pledge their support for an international coa-
lition of virology institutions, ready to act in times of outbreaks and
committed to advancing knowledge of pathogenic viruses. Today,
the GVN is comprised of 38 Centers of Excellence and 6 Affiliates in
24 countries (Fig. 1). Centers are led by world-class virologists who
have expertise in two or three areas of virology, strong publication
records, a commitment to building technical and scientific capac-
ities in resource-poor countries, and the readiness to support the
GVN infrastructure.3. The 2016 Robert C. Gallo Award
Albert Osterhaus, PhD, DVM, Director of the Research Center for
Emerging Infections and Zoonoses (RIZ) at the University of Vet-
erinary Medicine Hannover, Germany, a GVN Center of Excellence,
was presented with the Robert C. Gallo Award for Scientific Excel-
lence and Leadership for his pioneering contributions to influenza
and coronavirus research as well as his contributions to advancing
the GVN mission. Osterhaus was cited for his decades-long career,
which has included the discovery of more than 50 new human and
animal viruses and helping the WHO to combat outbreaks of MERS
(Middle East Respiratory Syndrome), SARS (Severe Acute Respira-
tory Syndrome), and pandemic influenza. He was also praised as a
leader within the GVN for his active participation in international
conferences and virology training programs, for making important
basic science contributions to medical virology and for translating
those contributions into broad public health initiatives.
The award is named for Robert C. Gallo, MD, the Director of the
Institute of Human Virology at the University of Maryland at Bal-
timore, and the Co-founder and Scientific Director of the GVN. Dr.
Gallo and colleagues discovered the first human retroviruses, hu-
man T-cell leukemia virus (HTLV)-1 and -2; and human
herpesvirus-6, which was subsequently demonstrated by others to
cause roseola (Gallo, 2005). Gallo co-discovered the human im-
munodeficiency virus (HIV) as the cause of AIDS and together with
colleagues discovered one of the first cytokines (IL-2). IL-2 later
became critical to growing continuous in vitro cell-lines, and is now
important in many immune therapy protocols. Dr. Gallo and col-
leagues also developed the first blood tests for HTLV-1 and HIV.4. Joint GVN-JSV symposium on translational virology
Robert Gallo reviewed recent HIV vaccine trials that used four
different methods. The Thai-U.S. Army trial (RV144) appeared to
have given very modest protection in the early months after
vaccination, while the others failed to prevent infection or in one
case was associated with greater infection. Gallo explained that for
the last several years, the emphasis has been on induction of an-
tibodies to the HIV envelope component, gp120, rather than to a
primary induction of cellular immunity to prevent infection. This
approach was based on the logic of trying to prevent integration
and establishment of a permanent infection. This effort has mainly
evolved around two programs. The first was a detailed analysis of
the RV144 results, particularly correlates of protection, which have
mainly highlighted antibodies interacting with VIV2 gp120 epi-
topes and epitopes induced by gp120 interactions with CD4,
referred to as CD4i Abs, which target conserved envelope regions
needed for gp120 interaction with CCR5. Functional correlations
were mainly with Fc effector functions rather than neutralizing
antibodies (Nab). The second major approach is one that is geared
toward inducing broad Nab, which is a reasonable goal, but one that
is not being met, as it is proving far more difficult than supposed.
Moreover, in studies in nonhuman primates (NHP), as well as the
results with RV144, correlation of protection is rare with Nab, even
when they are generated.
Gallo also described a candidate immunogen expressed as a
chimeric protein of gp120 and CD4, which has shown some efficacy
Fig. 1. The global reach of the GVN in 2017. Centers of Excellence are shown in blue and Affiliate sites in green. For information about Centers, Affiliates and participating scientists,
go to http://www.gvn.org/.
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CD4i antibodies that have Fc effector activity (Fouts et al., 2015).
This vaccine is in Phase I trials (https://clinicaltrials.gov/show/
NCT02756208). Like all anti-gp120 antibodies correlating with
protection, these antibodies do not persist, and attempts to increase
persistence have resulted in hyper-activation of T-cells, which then
formmore targets for HIV infection. Persistent boosting tomaintain
the antibodies leads to changes in the antibody isotype, which can
reduce their efficacy. Based on the RV144 trial and recent NHP
studies, Gallo concluded that two critical basic science problems
remain to be solved for the development of a successful anti-
envelope HIV vaccine: durability of the antibodies and a correct
immune balance.
Yasushi Kawaguchi, at the University of Tokyo, described cell
factors that are involved in a unique nuclear-pore-independent
export system for macromolecular complexes in the nucleus, and
which may be potential targets for novel anti-herpetic drugs.
Vesicle-mediated nucleocytoplasmic transport is a unique mecha-
nism for nuclear export of macromolecular complexes in which a
complex in the nucleus buds through the inner nuclear membrane
to form a vesicle in the perinuclear space (primary envelopment).
The vesicle then fuses with the outer nuclear membrane to release
the complex into the cytoplasm (de-envelopment). This type of
transport is observed in herpesvirus-infected mammalian cells for
export of viral nucleocapsids, but is not common in other types of
cells, indicating that herpesviruses may expropriate this mecha-
nism (Oda et al., 2016). However, the cellular mechanism for
vesicle-mediated nucleocytoplasmic transport remains largely
unknown. He went on to describe recently identified host cell
proteins involved in this unique nuclear export system, and how
these proteins could be targets for novel anti-herpetic drugs, since
this transport system is essential for the life cycle of herpesviruses
and is unique in biology.
Hideki Hasegawa, a GVN center director at the National Institute
of Infectious Diseases in Tokyo, explained that secretory IgAantibodies onmucosal surfaces play an important role in protection
against influenza virus infection. Secretory, polymeric IgA anti-
bodies induced by intranasal, inactivated influenza vaccine have
higher neutralizing and cross-neutralizing ability against homolo-
gous and heterologous influenza viruses compare to monomeric
IgA antibodies in humans (Suzuki et al., 2015). A method of pro-
ducing secretory multimeric IgA antibodies in vitrowas established
recently, and Hasegawa and colleagues examined the improvement
of neutralizing effects by multimerization using monoclonal IgA
antibodies. The method of in vitro production of multimeric IgA
antibodies was established by introducing cDNA constructs of H, L,
and J chains of IgA with secretory component (SC) into Expi293F
cells. This method allowed production of large amounts of recom-
binant monoclonal polymeric IgA antibody. The antibody-coding
cDNA was isolated and cloned from single plasma cell from the
peripheral blood mononuclear cells of a subject previously vacci-
nated intranasally with inactivated influenza A (H5N1) vaccine.
Monomeric and multimeric IgA antibody specific for influenza vi-
rus was prepared, and functional analysisdsuch as ELISA and
neutralization testsdwas performed. Similar to secretory IgA an-
tibodies in human nasal washes, the recombinant IgA showed that
polymerization of the antibody molecule enhanced the neutral-
izing activity. Mass spectrometry analysis found that the antibodies
had a molecular weight of 720 kDa, suggesting they consisted
mostly of the tetramer form. These tetrameric IgA antibodies may
be clinically useful as mucosal agents for the prevention and
treatment of influenza.
Erica Ollmann Saphire, a GVN center co-director at the Scripps
Research Institute (USA), reported on recent outbreaks of Ebola
virus disease and other viral diseases and the urgent need for novel
therapeutics. Monoclonal antibodies offer a promising solution to
the lack of currently available therapies, but it is often unclear how
to select the most effective antibodies or combinations for optimal
therapy (Saphire and Aman, 2016). Integrated analysis of a large
array of antibodies provides a rational basis for the selection of
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mechanisms underlying protective efficacy. She described the re-
sults of a field-wide analysis of antibodies against Ebola virus, a
particularly potent antibody against Marburg virus, and a novel
panel of antibodies against Lassa virus. A newly formed interna-
tional group, the Viral Hemorrhagic Fever Immunotherapeutic
Consortium, aims to galvanize and focus efforts against Ebola and
similar viruses, using multidisciplinary approaches (Saphire et al.,
2017).
Sharon Lewin, a GVN center director at the Doherty Institute for
Infection and Immunity (Australia), reported on HIV cure research
(Lederman et al., 2016). HIV persists predominantly in long-lived
resting CD4þ T cells that are found in blood and at greater fre-
quency in tissue. HIV can also persist in specific T-cell subsets
enriched in certain tissue sites, including T follicular helper cells in
lymph nodes and Th17 (CCR6þ) cells in the gastrointestinal tract.
Long-lived infectedmacrophages, specifically microglia in the brain
or Kupffer cells in the liver, may also play a role, though this re-
mains controversial. On ART, HIV-specific T cells express multiple
exhaustion markers, and these cells are often unable to recognize
and kill infected cells due to multiple immune escape mutations
that are archived in long lived latently infected cells. Furthermore,
in some tissue sites such as B-cell follicles in lymph nodes, there is
limited penetration of HIV-specific T-cells.
Lewin described several approaches that are being tested to
achieve HIV remission, including reducing latently infected cells
through early ART or latency reversal, boosting immune clearance,
reducing immune activation and homeostatic proliferation, elimi-
nating tissue reservoirs, and gene therapy to make cells resistant to
HIV. Recently completed clinical trials of latency-reversing agents
(LRA) in HIV-infected patients on ART have included histone
deacetylase inhibitors (HDACi) and high-dose disulfiram
(Delagreverie et al., 2016). Other interventions, including activation
of protein kinase C (PKC) with bryostatin and ingenols, are under
evaluation. Studies of HDACi and disulfiram have demonstrated
that HIV transcription can be activated in vivo with varying effi-
ciency, but to date there is no evidence that these interventions
alone can clear latently infected cells. In addition, recent in vitro
studies have shown that activating transcription with HDACi, but
not other LRAs, may lead to profound changes in HIV RNA splicing,
therefore limiting potency. Other concerns regarding HDACi
include short- and long-term toxicity, changes in host gene
expression and adverse effects on immune function. More potent
and specific LRAs are necessary and in development for use alone
and in combination. Additional interventions to promote cell death
may be needed.
Targeting BCL2 or inhibitors of anti-apoptotic proteins (IAP) is
being evaluated in vitro, and immune-mediated clearance with bi-
specific antibodies, broadly neutralizing antibodies and T-cell vac-
cines are in clinical development. However, even if the number of
latently infected cells is reduced, long-term immune control will be
required through therapeutic vaccination and/or immunomodula-
tion. Immune checkpoint blockers, including antibodies to CTLA-4
and PD-1 that have recently been licensed for the treatment of
melanoma, are potentially attractive tools to enhance HIV-specific
T-cells and reverse latency. Clinical trials of these agents are now
starting in HIV-infected individuals with malignancies.
5. Scientific presentations
5.1. Hepatitis C
Shyamasundran Kottilil, at the Institute of Human Virology
(USA), described the challenges of current treatments of chronic
hepatitis C. Eighty-five percent of HCV infections become chronic;20e30% of those cases will develop cirrhosis, and 5e10% of these
patients will progress to hepatocellular carcinoma and/or decom-
pensation of the liver, leading either to death or liver
transplantation.
In contrast to chronic hepatitis B or HIV infection, chronic HCV
infection can be cured with direct-acting antiviral (DAA) treatment.
“Cure” is defined in terms of sustained virologic response (SVR),
which is the absence of detectable levels of HCV RNA in the plasma
after 12 or 24 weeks of DAA treatment (Jazwinski and Muir, 2011).
Current HCV inhibitors act against the NS3/4 protease (e.g., asu-
naprivir and grazoprevir), the NS5A protein (e.g., daclatasvir and
velpatasvir) and the NS5B polymerase (e.g., sofosbuvir and becla-
buvir). Treatment with a combination of the two inhibitors,
sofosbuvir and velpatasvir, for 12 weeks, will result in a cure of
more than 99% of treated patients. Still, clinical challenges remain,
including treatment of patients with end-stage liver and renal
disease owing to metabolism and/or toxicity of the drugs. Other
challenges include the treatment of HIV/HCV co-infections, injec-
tion drug users, pediatric patients and maternal-fetal transmission
and pregnancy.
Estaban Domingo, at the Centro de Biología Molecular Severo
Ochoa in Spain, presented studies on the population dynamics of
HCV after antiviral interventions in infected human hepatomaHuh-
7.5 cells. Unexpectedly, serial passage of HCV in these cells in the
absence of antiviral drugs resulted in increased resistance to in-
hibitors that target viral or cellular proteins, and was associated
with a fitness gain of the virus.
If DAA-resistance mutations become widespread in human
populations, alternative drug treatments will be needed. One such
drug is favipiravir (Furuta et al., 2013). This is a broad-spectrum
antiviral agent active against numerous RNA viruses, including
influenza, norovirus, rabies, and Rift Valley fever virus. It acts as a
lethal mutagen (de Avila et al., 2016). Efficacy and safety trials of
favipiravir for treating influenza, as well as Ebola virus disease,
already have been done. In cell cultures], the efficacy of favipiravir
against HCV was found to be comparable to its efficacy against
other RNA viruses. In HCV-infected Huh-7.5 cells, favipiravir
demonstrated features typical of lethal mutagenesis. It was
concluded that favipiravir offers an alternative for patients chron-
ically infected with HCV.
5.2. Special session
Research on biomarkers of progression in human papil-
lomasvirus (HPV)-related cancers was highlighted in this session by
Franco Buonaguro (National Cancer Institute, Italy). Buonaguro
described persistent infections with high-risk HPVs that are often
associated with progression to mucosal cancers in anogenital as
well as oropharyngeal areas of the body. He also noted that for
cervical cancers, for which screening programs are available, it is
difficult to identify the lesions likely to progress to invasive cancers.
Given that only 1 in 500 HPV16-positive cervical dysplasias will
eventually progress further, biomarkers clearly are needed. Tumor
progression is characterized by increased expression of the viral E6
gene and E6-dependent degradation of p53, and increased
expression of E7, which is known to bind and inactivate pRb; and
integration of viral DNA into the host genome with the consequent
disruption of the E2 viral gene (Annunziata et al., 2012).
Molecular markers able to identify viral infections associated
with progressing cervical neoplasia are strongly needed for
screening and triage. In particular, predictive biomarkers are
needed to detect lesions at high risk of recurrence or progression, in
order to implement appropriate treatment and to avoid over-
treatment of patients with a high probability of regression. To
achieve such goals, expression profile analysis of p53-related genes
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tumor tissue, was performed, and significant differences in the
expression levels of genes involved in regulation of apoptosis, cell
cycle, proliferation and DNA repair pathways were identified.
Moreover, oncogenic driver mutations in critical genes (such as
PIK3CA and TP53), recurrent chromosomal gain/loss, and oncogene
activation by HPV integration have all been recognized to cause
deregulation of cell signaling pathways and cancer progression
(Tornesello et al., 2014). More recently, analysis of the regulatory
regions of human genes encoding for cell proliferation proteins has
shown a high frequency of mutations in lesions associated with less
oncogenic HPV genotypes, and even in HPV-negative lesions.
Validation of these candidate biomarkers is currently under way on
a larger number of cases, including different grades of HPV-related
neoplastic lesions (CIN1-3 and invasive cervical cancer). Such
studies will contribute to the development of new tools for the
identification of premalignant lesions at high risk of progression to
invasive cervical carcinoma.
Jonathan Gershoni, a GVN center director at Tel Aviv University
(Israel), described an analysis of the vast repertoire of antibodies
circulating in polyclonal serum (the “IgOme.”) He highlighted how
the paratope region of an antibody mirrors the corresponding re-
gion of an antigen (e.g., a virus protein) and therefore favors an
indirect approach of IgOme profiling by describing all peptides
interacting with the entity of antibodies. The spectrum of antibody
specificities is dynamic and varies with age, physiology, and
exposure to pathological insults. The IgOme is an extraordinarily
rich source of informationea molecular record of all previous en-
counters, as well as a status report of current immune activity
(Weiss-Ottolenghi and Gershoni, 2014). The ability to profile anti-
body specificities of polyclonal serum at very high resolution has
been an important and serious challenge, which can now bemet by
probing, recording, and qualifying the archive of antibodies present
in the serum of an individual with a vast library of peptides.
Gershoni also described “Deep Panning”, a methodology that
merges the flexibility of combinatorial phage-display peptide li-
braries with the power of next-generation sequencing to enable
high-resolution/high-throughput interrogation of the IgOme
(Ryvkin et al., 2012). This approach produces heat-maps that
characterize the interaction between the immune system and an-
tigens. This method was used to characterize and differentiate sera
from HIV-infected individuals versus HCV-infected individuals. By
analyzing the immune response to influenza antigens in birds,
Jonathan showed that this technique could be used to monitor and
characterize the efficiency of vaccines, suggesting that IgOme
analysis may become a very useful tool for vaccine development.
5.3. Arboviruses
Since the appearance of chikungunya virus (CHIKV) in the
Western Hemisphere in 2014, the GVN has had a special focus on
arboviruses. In 2014, the Network sponsored a joint symposium
with the American Society of Tropical Medicine and Hygiene on
“The Global Spread of Chikungunya: Epidemiology, Evolution,
Pathogenesis and Global Needs” and published a special report
describing research goals and public health priorities for the
outbreak (McSweegan et al., 2015). A task force of international
experts also was formed to provide a source of expert information
and a platform for collaboration.
Marc Lecuit at the GVN center at the Institut Pasteur in Paris
described CHIKV, its geographical spread, the clinical presentation
of infection and the development of a mouse model that has
allowed pathophysiology studies and the evaluation of novel
therapeutics. Murine fibroblasts of skeletal muscles, joint capsules
and dermis were found to be primary viral targets, and type I IFN-sensing, non-hematopoietic cells were critical for innate immune
control. A genome-wide siRNA screen identified 156 proviral and
41 antiviral host factors affecting viral replication, which allowed
identification of potential drug targets. Twenty-one small molecule
inhibitors that affect six host pathways have been identified; three
showed prophylactic effects in the mouse model. A calmodulin
inhibitor (pimozide) and a fatty acid synthesis inhibitor (TOFA)
showed antiviral effects in mice when used together (Karlas et al.,
2016). Other experimental data showed that CHIKV infection does
not directly target the placental barrier, therefore vertical trans-
mission from viremic mothers to neonates likely occurs via labor-
induced placental breaches. CHIKV also was found to be a signifi-
cant cause of CNS disease in larger human outbreaks, with the virus
detected in affected tissues (Gerardin et al., 2016).
Scott Weaver, Chair of a GVN task force on Zika virus (ZIKV),
reviewed the sudden emergence of ZIKV from relative obscurity to
global menace. Serosurveys have shown its historical incidence in
parts of Asia and Africa (Weaver et al., 2016). A widespread
outbreak in theMicronesian island of Yap in 2007 later expanded to
neighboring islands in South Pacific. Coincident with these out-
breaks, a 20-fold higher incidence of Guillain-Barre syndrome
(GBS) was noted. The explosive outbreak in Brazil that began in
2015 and has involved millions of people has since spread to 47
other countries and territories in the Western Hemisphere. The
peridomestic mosquito, Aedes aegypti, and the invasive Aedes
albopictus mosquito have been identified as the major insect vec-
tors. Surprisingly, sexual transmission of ZIKV also was confirmed
in travelers returning to non-endemic regions. A most disturbing
aspect of the recent outbreaks is the high incidence of fetal
microcephaly and other birth defects directly related to infection in
pregnant women.
Weaver also discussed important knowledge gaps. When and
how should infants be tested for possible congenital Zika infection?
Is microcephaly among some neonates just the tip of the neuro-
logical iceberg? Why does the overall risk of microcephaly and
other birth defects seem to differ in other parts of Latin America
and the Caribbean, compared to Brazil? It appears that these new
outbreaks in the Western Hemisphere have not been caused by
novel viral strains. Instead, the introduction of ZIKV into naïve
populations via rapid global travel, the growth of tropical cities, and
changing vector populations seem to have allowed virus amplifi-
cation and subsequent epidemic spread. Prospects for control are
dependent on mosquito control, new therapeutics and develop-
ment of an effective vaccine. Vaccine prospects appear good, with
about 40 candidates now in development and animal models
available for preclinical testing. Two DNA-based vaccines have
entered Phase I trials, and an inactivated vaccine is nearing Phase I.
Deploying a vaccine, however, remains dependent on developing
an accurate test for ZIKV. Current tests are hampered by antigenic
cross-reactivity between ZIKV and other closely related flaviviruses
such as dengue, yellow fever, and St. Louis encephalitis, some of
which are endemic in the same geographic areas.
Richard Scheuermann, GVN center co-director at the J. Craig
Venter Institute (USA), discussed using the Influenza Research
Database (IRD, fludb.org) and the Virus Pathogen Resource (ViPR,
viprbrc.org) to identify diagnostic peptide regions in Zika virus
(ZIKV) and other flaviviruses. These databases identified 76 and 82
diagnostic amino acid sites from the ZIKV NS1 and E proteins,
respectively, that distinguish it from other flaviviruses, with
sensitivity/specificity above 98% (Sun et al., 2017). Similar numbers
of such diagnostic sites were also identified for other flaviviral
species. Sliding window analysis revealed several contiguous pep-
tide regions that contain multiple diagnostic sites specific for each
of the different flaviviruses. These regions are now being used to
develop peptide arrays for the detection of antibodies specific for
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a significant impact on diagnosis and epidemiological analysis of
future disease outbreaks.
Diane Griffin at the GVN center at Johns Hopkins University
(USA) noted that insect-borne viruses causing encephalitis have
become a global health concern due to their recent expansion into
new regions.While the fatality rates vary, many patients recovering
from serious episodes of viral encephalitis are likely to have lifelong
physical and mental disabilities. Viral persistence and immune-
mediated clearance are important factors in these sequelae.
Griffin described experiments with Sindbis virusda prototype
alphavirusdusing a variety of mouse models (Griffin, 2016).
Infection of neurons in adult mice resulted in non-fatal encepha-
lomyelitis. Recovery was mediated through a coordinated effort
between antibody to the E2 viral surface protein and IFN-g. While
IFN-g signaling leads to clinical disease via pro-inflammatory cy-
tokines, it synergistically helps clear the virus by increasing B-cell-
attracting chemokine production for recruitment of antibody-
producing cells to the central nervous system (CNS). However,
the non-cytolytic immune phenomenon does not lead to elimina-
tion of intracellular viral RNA from long-lived neurons, so that
continued suppression of virus and the prevention of reactivation
and reemergence in the CNS require immune control after recovery.
Evidencewas presented that B and Tcells that infiltrated during the
acute phase of infection remain there after recovery and continue
to exert their protective effect locally. Long-term residence of these
immune cells in the CNS is likely facilitated by the continued
presence of viral proteins.
Arthropods make up the largest phylum of the animal kingdom
and are known to harbor and transmit viruses of agricultural, vet-
erinary and medical importance. The true extent of the ‘virosphere’
of arthropods, however, is largely unknown and needs to be more
completely explored. Yong-Zhen Zhang, an investigator at the Na-
tional Institute for Communicable Disease Control and Prevention
in Beijing, China, presented work on newly identified RNA viruses
from arthropods collected in different regions of China. Among
recent examples are Jingmen tick virus (JMTV), and viruses
belonging to a new family, Chuviridae (Qin et al., 2014). JTMV has
four genomic segments, and, sequence analysis has revealed an
unexpected connection between segmented and non-segmented
viruses. Chuviruses exhibit various genomic organizations,
including non-segmented, bi-segmented, and circular genomes.
These viruses provided evidence of an evolutionary link between
segmented and non-segmented negative strand viruses. Overall,
many novel viruses representing five new families, have been
discovered in China and await further characterization.
5.4. Vaccines
Peter Palese, a GVN center director at the Icahn School of
Medicine at Mount Sinai (USA), described ongoing efforts to design
a universal influenza vaccine and to understand the immune re-
sponses to such constructs. He said that, despite the availability of
FDA-approved vaccines and antivirals, seasonal and pandemic
influenza remain a serious threat associated with substantial
morbidity and mortality. While annual seasonal influenza virus
vaccination is effective e albeit underutilized in most countries e a
safe, universal vaccine providing broad and long-lasting immunity
would represent a major breakthrough. Today's licensed vaccines
focus on eliciting humoral immunity to the globular head (HA1) of
the hemagglutinin (HA) glycoprotein, an antigen subject to anti-
genic drift, which requires continued surveillance of circulating
influenza viruses. Since the 2009 H1N1 pandemic, research efforts
on universal vaccines have refocused, looking to shift immunity to
the more conserved domains of HA, which is expected to covermany more circulating influenza viruses.
Palese also has developed vaccine constructs that express
chimeric hemagglutinins (cHA) that result in the redirection of the
immune response away from the immunodominant (variant) HA1
head domain towards themuchmore conserved stalk (HA2) region,
and which also express the highly conserved neuraminidase (NA)
(Tran et al., 2016). This type of immunogen has been demonstrated
to be efficacious following vaccination in mice, conferring hetero-
subtypic protection against virus challenge. The mechanism by
which this approach confers antiviral activity suggests that re-
directing immunity to the stalk region preferentially supports in-
duction of antibody-dependent cell-mediated cytotoxicity (ADCC).
Data presented showed that broadly neutralizing HA stalk-specific
antibodies require FcgR interactions for protection. Palese proposed
a two-contact model for optimal induction of ADCC by influenza
virus-specific mAbs targeting the stalk regiondand not the glob-
ular headdand he noted the importance of the HA binding to
effector cells via its sialic acid receptor was required for optimal
ADCC induction. Passive transfer studies in mice further supported
the role of H1-specific stalk antibodies and protection against
weight loss following virus challenge.
This novel technology is being supported through government
and industry support, and GMP-quality batches of two cHA im-
munogens (cH5/1N1 & cH8/1N1) that display heterogenous glob-
ular heads have been produced for evaluation in the clinic. Such
studies will make it possible to assess the role of additional effector
mechanism in protecting against influenza virus infection and to
evaluate the importance of reducing the immunodominance of the
variable HA head domain. This type of translational study will bring
us a step closer to a universal influenza vaccine.
5.5. Zoonoses
Hiroshi Kida at Hokkaido University in Japan reported on the
establishment of a library of 2900 avian influenza virus strains
isolated from ducks, and reassortant viruses generated in the lab-
oratory, with 144 combinations of the nine NA and sixteen HA
subtypes (virusdb.czc.hokudai.ac.jp). Because influenza A viruses of
all known subtypes can perpetuate among migratory ducks and
contribute genes to the generation of reassortant viruses in pigs,
none of the 144 combinations can be ruled out as possible future
pandemic strains. This virus library is kept as a source for vaccine
candidates to assure effective preparedness for future pandemics
(Haredy et al., 2013). Vaccine constructs prepared from H1N1,
H5N1, H6N2, H7N7, H7N9 and H9N2 viruses in the library elicited
sufficient immune responses to protect chickens, mice, and ma-
caques from challenge with isolates from poultry and humans,
suggesting their utility against pandemic influenza.
In addition, he noted that current seasonal vaccines prepared by
ether or detergent disruption are not sufficiently immunogenic,
especially in children and the elderly, and need to be significantly
improved. Furthermore, methods for controlling pandemic influ-
enza should be based on measures that are used for the control of
seasonal influenza. Hiroshi noted that inactivated whole virus-
based vaccine candidates might provide solutions to the limita-
tions of current vaccines. To accomplish the goal of a new and
effective influenza vaccine, a collaborative research group, the All
Japan Collaborating Study Group For the Development of Influenza
Vaccines, was established in April 2015. Five Japanese manufac-
turers of influenza vaccines participate in the program. The goals of
the study group are: to compare the immunogenicity and safety of
whole virus particle vaccine and “split” vaccines; use the results of
pre-clinical and clinical trials to revise the standard of influenza
vaccines for human use; and determine the optimum route of
inoculation and evaluate proprietary adjuvants.
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of Glasgow Center for Virus Research (Scotland), reported on
studies of bluetongue, a major infectious disease of ruminants,
caused by the double-stranded RNA virus known as bluetongue
virus (BTV). Studies of BTV in sheep offer unique perspectives for
understanding the pathogenesis of arboviral diseases, as observa-
tions made in the naturally occurring disease can be effectively
reproduced in a convenient experimental setting, using the same
animal species (Caporale et al., 2014). The clinical outcome of BTV
infection in sheep is extremely variable, but similar to other arbo-
virus infections, in that a rapid onset of the antibody response
correlates with a more favorable clinical outcome. BTV infection of
its natural sheep host was used to examine a previously unchar-
acterized mechanism adopted by an arbovirus to manipulate host
immunity at the early stages of infection. BTV is transported rapidly
via the lymph to the peripheral lymph nodes, where it infects and
disrupts follicular dendritic cells (FDC). These cells of stromal origin
promote the formation and maintenance of the germinal centers in
which B cells differentiate into memory cells and plasma cells, and
are also responsible for supporting antibody class-switching and
affinity maturation. This work showed that BTV hindered B-cell
division in germinal centers, resulting in the delayed production of
high-affinity and virus-neutralizing antibodies. Importantly, the
humoral immune response to a second antigen is also hampered in
infected sheep. Thus, an arbovirus can evade the host antiviral
response by inducing an acute immunosuppression. Although
transient, this immunosuppression occurs at the critical, early stage
of infection, when a delayed host humoral immune response likely
affects the systemic dissemination of the virus and the clinical
outcome of disease (Melzi et al., 2016).
Ab Osterhaus, the GVN center director at the Research Center for
Emergin, reviewed the complex relationships among human and
animal species that have promoted cross-species transmission,
emergence and the eventual evolution of a plethora of human
pathogens. Changes affecting modern human populations world-
wide and their dramatic impact on the global environment have
taken domestication, agriculture, urbanization, and industrializa-
tion to unprecedented levels. This has created new and global
multi-faceted human-animal interfaces, associated with major
epidemiological transitions, accompanied by an unexpected surge
of emerging and re-emerging human infectious diseases that have
their origin in animal reservoirs.
Until the beginning of the last century, infectious diseases were
the major cause of human mortality. Around 1900, infections
caused about fifty percent of deaths in thewesternworld, but in the
following decades, this percentage decreased to less than a few
percent. This was largely due to the implementation of public
health measures such as the installation of sewers and the devel-
opment of clean drinking water systems, but also to development
of vaccines and antimicrobials. Major successes in this regard were
the eradication of smallpox and rinderpest through well-
orchestrated vaccination campaigns in humans and cattle, respec-
tively. These successes prompted policymakers and scientists to
predict that infectious diseases of humankind and of their domestic
animals would eventually be brought under control in the indus-
trialized world.
Paradoxically the following decades confronted the world with
an ever-increasing number of emerging or re-emerging infectious
diseases, some causing true human or animal pandemics. Patho-
gens spilling over from wildlife reservoirs, either directly or via
intermediate hosts, were the basis of most of the outbreaks. Strik-
ing examples in humans were the emergence of AIDS from chim-
panzees, avian flu frommigratory birds, and SARS, MERS, and Ebola
virus disease from bat reservoirs. A complex mix of predisposing
factors in our globalizing world, linked to major changes in thesocietal environment and global ecology, collectively created op-
portunities for viruses and other pathogens to infect and adapt to
new animal and human hosts. This paved the way for the unprec-
edented spread of infections, with dramatic consequences for
public and animal health, animal welfare, food supplies, economies,
and biodiversity. It is important to realize that, because of the
complex and largely interactive nature of the predisposing factors,
it is virtually impossible to predict the next pathogen threat, where
it will come from and when it will strike. However, a better un-
derstanding of the underlying processes may eventually lead to
enhanced predictive capacity, improving preparedness for out-
breaks in humans and animals. Importantly, the increased emer-
gence of viral infections has been largely paralleled by medical,
veterinary, technological, and scientific progress. Investments to
better understanding human-animal interfaces should offer a
future head start in the struggle against infectious diseases of
humans.
Ayato Takada at the Global Institution for Collaborative Research
and Education at Hokkaido University in Sapporo, Japan, described
an Ebola virus glycoprotein-specific monoclonal antibody (mab
6D6) that was broadly cross-reactive with all known Ebola virus
species. This mab recognized the putative epitope in the highly
conserved internal fusion loop (IFL) and neutralized infectivity by
inhibiting membrane fusion. Mab 6D6 may, therefore, have po-
tential as a therapeutic agent in animal models. He also described a
novel antibody-dependent enhancement (ADE) mechanism in
which Fc receptor-mediated intracellular signaling increased up-
take of Ebola virus into cells in vitro (Furuyama et al., 2016). Acti-
vation of the Fc-receptor-mediated signaling pathwaywas essential
for ADE of Ebola virus infection; this finding provides new insights
into mechanisms of ADE and the development of treatments for
ADE-associated diseases. Finally, he noted that neutralizing and
ADE antibodies show balanced effects depending on total antibody
concentration, raising theoretical concerns about the use of
convalescent human sera or plasma with low antibody titers.
Therapeutic treatment with convalescent sera with in vitro
neutralizing activity was not sufficient to protect against Ebola vi-
rus infection in nonhuman primates (Mire et al., 2016). It may be
that ADE antibodies counterbalanced the neutralizing capacity of
other antibodies. These laboratory phenomena warrant further
evaluation.
5.6. Retroviruses
Luc Willems, a GVN investigator at Gembloux Agro-Bio Tech in
Belgium, described how bovine delta-retroviral ribonucleic acids
induce cell transformation and oncogenesis. Among the strategies
developed by viruses to escape the host immune response, mech-
anisms involving viral non-coding RNAs have recently been
discovered. Viruses can express microRNAs that directly target
cellular transcripts, while others produce long non-coding RNAs
acting as microRNA sponges or epigenetic modulators. These stra-
tegies, based on ribonucleic acids, control the cell's fate without
eliciting immune responses due to the absence of viral proteins.
Virally encoded miRNAs were first identified in DNA viruses. Most
of them are generated from endonucleolytic cleavage of long viral
transcripts. However, retroviruses were initially assumed not to
encode miRNAs because of the potential self-cleavage of their RNA
genome (Gillet et al., 2016).
To date, four retroviruses – bovine leukemia virus (BLV), bovine
foamy virus (BFV), avian leucosis virus (ALV-J) and simian foamy
virus (SFV) e have been shown to express viral miRNAs in infected
cells. BLV naturally infects bovine species to cause a benign
lymphocytosis, but approximately 5% of infections lead to B-cell
leukemia/lymphoma. Remarkably, BLV persists and replicates
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scription. In contrast, BLV miRNAs are highly expressed in infected
cells, representing up to 40% of all cellular miRNAs. Consequently,
because ribonucleic acids likely are less immunogenic than viral
protein antigens, BLV miRNAs could alter the cell's fate by escaping
immune recognition (Gillet et al., 2016).
6. The network in 2016
As with the 2014 appearance of CHIKV in the Western Hemi-
sphere, the sudden emergence and dissemination of ZIKV have
driven similar cooperative responses at the GVN, including the
formation of a second task force of experts to exchange information
and share resources; the organization of a webinar for business
leaders to inform them about the virus and prospects for therapies
and vaccines (http://www.btsmeetings.com/zika); providing
expert information to the newsmedia to ensure accurate reporting;
and acquiring a grant from the Allergan Foundation to establish a
bank of acute and convalescent sera from confirmed ZIKV patients
to aid in developing better diagnostics.
Among other accomplishments, Shyamasundran Kottilil and
colleagues at the Institute of Human Virology in Baltimore began a
project with the GVN, and funded by the Gilead Foundation, to
develop a training model for physicians using DAA treatment for
HCV patients in India. Members of the HTLV-1 task force published
a commentary on the need for HTLV-1 screening prior to organ
transplant, and an agenda for future research (Gallo et al., 2016;
Willems et al., 2017). Other GVN investigators published new
research onWest Nile virus and rabies virus (Kobayashi et al., 2016;
Phongphaew et al., 2017; Anindita et al., 2016).
During the past year, the Network expanded the number of
cooperating research centers by adding the University of Miami,
Emory University and Tulane University School of Medicine in the
USA and the International Vaccine Institute in South Korea (http://
gvn.org/coe/). These centers are expected to strengthen cooperative
research on vaccines, antiviral drugs, and emerging viruses such as
ZIKV and Ebola virus.
7. Plans for 2017
Among other projects, the GVN staff in Baltimore expects to
assist with a pilot study of hepatitis B in Arunachal Pradesh, India.
Funded by the John Martin Foundation, the project will screen
30,000 people, provide vaccinations for those who are not infected,
and develop a longitudinal cohort to treat patients with chronic
hepatitis B infections.
Members of the GVN task force on HTLV-1 expect to publish
additional commentaries and reviews during 2017. Similarly, a GVN
task force report on ZIKV emergence and research priorities is in
preparation. GVN staff also will continue to seek additional patient
serum samples for the ZIKV serum bank based at the University of
Texas Medical Branch in Galveston, Texas. Additionally, a project to
sequence and conduct phylogenetic analyses of collected Zika virus
isolates has begun in cooperation with the World Reference Center
for Emerging Viruses and Arboviruses (WRCEVA), which is funded
by the National Institute of Allergy and Infectious Diseases (USA).
The GVN will host its fourth annual Short Course on Medical
Virology for young investigators. The Short Course attracts an in-
ternational class of 15e20 postdoctoral students and fellows for
five days of meetings and lectures with experts in medical virology
research and clinical practice. Information about the course and
registration is available online at http://www.gvn.org.
The 2017 international GVN meeting will be in Melbourne,
Australia during September 25e27. It will be co-hosted by the GVN
Centers of Excellence, the Institut Pasteur (Paris) and the PeterDoherty Institute for Infection and Immunity (Melbourne). The
Scientific Organizing Committee includes Sharon Lewin, Director,
The Peter Doherty Institute for Infection and Immunity, Australia;
Robert Gallo, Co-Founder & Scientific Director, GVN, Institute of
Human Virology at the University of Maryland School of Medicine;
William Hall, Co-Founder, GVN, University College Dublin; Dr. Marc
Lecuit, Director of the Biology of Infection Unit at Institut Pasteur,
France; Damian Purcell, Viral Infectious Diseases, Doherty Institute,
Australia; Peter Revill, Senior Medical Scientist, Victorian Infectious
Diseases Reference Laboratory, Australia; and Didier Fontenille,
Director, Institut Pasteur in Cambodia. Among the major topics of
the 2017 meeting will be HTLV-1 infections among indigenous
Australian populations; emerging viruses in Australia and South-
east Asia; and viruses causing hemorrhagic syndromes and
persistent infections.Acknowledgements
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